{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:24:38Z","timestamp":1794428678106,"version":"4.9.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG084635"],"award-info":[{"award-number":["RF1AG084635"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cytogfr.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:52:24Z","timestamp":1758592344000},"page":"40-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Designing immunity with cytokines: A logic-based framework for programmable CAR therapies"],"prefix":"10.1016","volume":"86","author":[{"given":"Saurabh","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Upmanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib1","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR t cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.09.004_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor t cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","article-title":"CAR-T cells: early successes in blood cancer and challenges in solid tumors","volume":"11","author":"Dana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084170","article-title":"Car t cells in solid tumors: overcoming obstacles","volume":"25","author":"Rojas-Quintero","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib5","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: an overview of current understandings (Review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2025.09.004_bib7","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib8","doi-asserted-by":"crossref","first-page":"1615212","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.09.004_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR t cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.09.004_bib13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","article-title":"IL-15 preconditioning augments CAR t cell responses to checkpoint blockade for improved treatment of solid tumors","volume":"28","author":"Giuffrida","year":"2020","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.09.004_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00262-024-03756-9","article-title":"Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma","volume":"73","author":"Wu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.09.004_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102515","article-title":"Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform","volume":"20","author":"Fang","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/sci.2019.05.02","article-title":"Lineage switch from T-cell lymphoblastic leukemia\/lymphoma to acute myeloid leukemia and back to T-cell lymphoblastic leukemia\/lymphoma in a patient diagnosed during pregnancy","volume":"6","author":"Aujla","year":"2019","journal-title":"Stem Cell Invest."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR t cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.09.004_bib18","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"628","key":"10.1016\/j.cytogfr.2025.09.004_bib19","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor t cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"103","key":"10.1016\/j.cytogfr.2025.09.004_bib20","doi-asserted-by":"crossref","first-page":"eado2054","DOI":"10.1126\/sciimmunol.ado2054","article-title":"Trogocytosis of chimeric antigen receptors between t cells is regulated by their transmembrane domains","volume":"10","author":"Barbera","year":"2025","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib21","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR t cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.09.004_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","article-title":"Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy","volume":"14","author":"Merz","year":"2024","journal-title":"Blood Cancer J."},{"issue":"7952","key":"10.1016\/j.cytogfr.2025.09.004_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR t cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.09.004_bib26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J. Clin. Immunol."},{"issue":"47","key":"10.1016\/j.cytogfr.2025.09.004_bib28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR t strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"591","key":"10.1016\/j.cytogfr.2025.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR t cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.cytogfr.2025.09.004_bib31","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive Interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib32","doi-asserted-by":"crossref","first-page":"1258156","DOI":"10.3389\/fimmu.2023.1258156","article-title":"Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor t cells","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.09.004_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.09.004_bib34","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","article-title":"A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced t lymphocytes and antitumor activity","volume":"183","author":"Zhao","year":"2009","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.09.004_bib35","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.09.004_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of t cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"26","key":"10.1016\/j.cytogfr.2025.09.004_bib38","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41591-024-02928-5","article-title":"Author correction: locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.09.004_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor t cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib43","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of t cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-024-01955-7","article-title":"The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS\/MAPK-driven melanoma","volume":"23","author":"Feichtenschlager","year":"2024","journal-title":"Mol. Cancer"},{"issue":"625","key":"10.1016\/j.cytogfr.2025.09.004_bib46","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR t cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib48","doi-asserted-by":"crossref","first-page":"1384249","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.09.004_bib49","first-page":"6137","article-title":"NF-kappa b subunit-specific regulation of the interleukin-8 promoter","volume":"13","author":"Kunsch","year":"1993","journal-title":"Mol. Cell Biol."},{"issue":"34","key":"10.1016\/j.cytogfr.2025.09.004_bib50","doi-asserted-by":"crossref","first-page":"20545","DOI":"10.1074\/jbc.271.34.20545","article-title":"The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor","volume":"271","author":"Ahuja","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.cytogfr.2025.09.004_bib51","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor t cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib54","first-page":"565","article-title":"INSPIRED symposium part 5: expanding the use of CAR t cells in children and young adults","volume":"30","author":"Talleur","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib55","article-title":"Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"Pt 2","key":"10.1016\/j.cytogfr.2025.09.004_bib56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","volume":"86","author":"Bhatia","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.09.004_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020843","article-title":"The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature","volume":"22","author":"Korbecki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2019.00216","article-title":"Heparanase promotes tumor growth and liver metastasis of colorectal cancer cells by activating the p38\/MMP1 axis","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.09.004_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001965","article-title":"High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer","volume":"9","author":"Bareche","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.09.004_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103961","article-title":"Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Hong","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.09.004_bib62","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.09.004_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110863","article-title":"Validation of a PD-1\/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous b cell lymphoma","volume":"27","author":"Yoshimoto","year":"2024","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.09.004_bib64","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-Targeted human CAR t cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci."},{"issue":"5-6","key":"10.1016\/j.cytogfr.2025.09.004_bib66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2021.050","article-title":"Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered t cells","volume":"33","author":"Qu","year":"2022","journal-title":"Hum. Gene Ther."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.09.004_bib67","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12998\/wjcc.v12.i18.3555","article-title":"Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: a case report","volume":"12","author":"Zhou","year":"2024","journal-title":"World J. Clin. Cases"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth Factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40364-020-00238-9","article-title":"Engineering t cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing","volume":"8","author":"Liao","year":"2020","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib70","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor-specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib71","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2022.5097","article-title":"A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of t cells is controlled by expression patterns of cell\u2011surface proteins on target cells","volume":"49","author":"Aoyama","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR t cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib74","first-page":"584 e1","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large b cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transpl. Cell Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010644","article-title":"The mechanisms of altered blood-brain barrier permeability in CD19 CAR T-cell recipients","volume":"25","author":"Pinto","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib76","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijid.2021.07.021","article-title":"Tocilizumab and systemic corticosteroids in the management of patients with COVID-19: a systematic review and meta-analysis","volume":"110","author":"Alkofide","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.09.004_bib77","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib78","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/00912700122010771","article-title":"Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers","volume":"41","author":"Iuliucci","year":"2001","journal-title":"J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib79","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A rapamycin-activated caspase 9-based suicide gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.09.004_bib80","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1089\/hum.1995.6.12-1525","article-title":"The thymidine kinase\/ganciclovir-mediated \"suicide\" effect is variable in different tumor cells","volume":"6","author":"Beck","year":"1995","journal-title":"Hum. Gene Ther."},{"issue":"23","key":"10.1016\/j.cytogfr.2025.09.004_bib81","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib82","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European myeloma network perspective on CAR T-Cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib83","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1038\/s41598-020-70022-0","article-title":"Optimisation of Tet-On inducible systems for sleeping Beauty-based chimeric antigen receptor (CAR) applications","volume":"10","author":"Ali Hosseini Rad","year":"2020","journal-title":"Sci. Rep."},{"issue":"6_","key":"10.1016\/j.cytogfr.2025.09.004_bib84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"499","key":"10.1016\/j.cytogfr.2025.09.004_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR t cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.09.004_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and t cell cytotoxicity following stimulation with t cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib87","doi-asserted-by":"crossref","first-page":"9751","DOI":"10.1038\/s41467-024-54150-z","article-title":"Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"575","key":"10.1016\/j.cytogfr.2025.09.004_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.cytogfr.2025.09.004_bib89","article-title":"Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting","author":"Wang","year":"2025","journal-title":"Cell Rep. Med"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib90","article-title":"Hypoxia-sensing CAR t cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep. Med"},{"issue":"47","key":"10.1016\/j.cytogfr.2025.09.004_bib91","doi-asserted-by":"crossref","first-page":"20246","DOI":"10.1073\/pnas.1014403107","article-title":"pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation","volume":"107","author":"An","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"81","key":"10.1016\/j.cytogfr.2025.09.004_bib92","doi-asserted-by":"crossref","first-page":"eadf1426","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib93","doi-asserted-by":"crossref","first-page":"1545270","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib94","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t Cell-Induced severe or Life-Threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib95","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming t cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib96","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","article-title":"CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications","volume":"13","author":"Feng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109625","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges","volume":"121","author":"McGowan","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.09.004_bib99","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41423-020-0436-5","article-title":"Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) t cells to enhance viral and tumor immunity","volume":"18","author":"Shan","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"8010","key":"10.1016\/j.cytogfr.2025.09.004_bib100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR t cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008665","article-title":"NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors","volume":"12","author":"Nakagawara","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.09.004_bib102","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.09.004_bib103","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR t cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.09.004_bib104","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by t cells redirected with an optimized GD2-Specific chimeric antigen receptor and Interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib106","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces t cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J. Exp. Med"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.09.004_bib108","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","article-title":"Enforced PGC-1alpha expression promotes CD8 t cell fitness, memory formation and antitumor immunity","volume":"18","author":"Dumauthioz","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.09.004_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102609","article-title":"MicroRNA-responsive ON-OFF hybrid mRNA switch for precise protein expression control","volume":"36","author":"Masaki","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042416","article-title":"Harnessing the transcriptional signatures of CAR-T-Cells and Leukemia\/Lymphoma using single-cell sequencing technologies","volume":"25","author":"Liao","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib113","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cac2.12012","article-title":"Emerging role of deep learning-based artificial intelligence in tumor pathology","volume":"40","author":"Jiang","year":"2020","journal-title":"Cancer Commun."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807696","article-title":"Revealing clonal responses of tumor-reactive T-Cells through t cell receptor repertoire analysis","volume":"13","author":"Aoki","year":"2022","journal-title":"Front Immunol."},{"issue":"ement 1","key":"10.1016\/j.cytogfr.2025.09.004_bib115","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim phase I clinical data of FT819-101, a study of the first-ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell therapy for patients with relapsed\/refractory B-Cell malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib116","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1534\/genetics.112.140855","article-title":"Insertional mutagenesis by a hybrid piggybac and sleeping beauty transposon in the rat","volume":"192","author":"Furushima","year":"2012","journal-title":"Genetics"},{"issue":"7643","key":"10.1016\/j.cytogfr.2025.09.004_bib117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.09.004_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR t cells","volume":"10","author":"Lock","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"ement_1","key":"10.1016\/j.cytogfr.2025.09.004_bib119","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with Relapsed\/Refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR t therapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.09.004_bib121","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR t cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory b cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib122","first-page":"xi12","article-title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"issue":"ement 1","key":"10.1016\/j.cytogfr.2025.09.004_bib123","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.cytogfr.2025.09.004_bib124","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cytogfr.2025.09.004_bib125","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.cytogfr.2025.09.004_bib126","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/cancers17142397","article-title":"Engineering innate immunity: recent advances and future directions for CAR-NK and CAR\u2013Macrophage therapies in solid tumors","volume":"17","author":"Amoozgar","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.09.004_bib127","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.09.004_bib128","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/bit.25175","article-title":"Lentivirus delivery of IL-10 to promote and sustain macrophage polarization towards an anti-inflammatory phenotype","volume":"111","author":"Boehler","year":"2014","journal-title":"Biotechnol. Bioeng."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.09.004_bib129","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.19988","article-title":"mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells","volume":"206","author":"Chen","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cytogfr.2025.09.004_bib130","doi-asserted-by":"crossref","first-page":"1457629","DOI":"10.3389\/fimmu.2024.1457629","article-title":"Unlocking the potential of iPSC-derived immune cells: engineering iNK and it cells for cutting-edge immunotherapy","volume":"15","author":"Fang","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.09.004_bib131","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2025.13587","article-title":"IPSC\u2011derived NK cells for immunotherapy and therapeutic perspective (Review)","volume":"32","author":"Wei","year":"2025","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib132","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.09.004_bib133","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:26:57Z","timestamp":1781234817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":133,"alternative-id":["S1359610125001327"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.09.004","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing immunity with cytokines: A logic-based framework for programmable CAR therapies","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}